Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Dassault Systèmes SE    DSY   FR0000130650

DASSAULT SYSTÈMES SE

(DSY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Dassault Systemes : Avance Clinical and Medidata Celebrate Strategic Partnership and Inhouse Expert Accreditation Milestones

02/26/2021 | 03:49am EDT

ADELAIDE, AU, Feb 26, 2021 - (ACN Newswire) - - The leading Australian CRO for biotechs, and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical continues to celebrate their strategic partnership with Medidata, and the accreditation of seven Medidata inhouse experts.

The two organizations have been working together to deliver world-class clinical research services to Avance Clinical's biotech customers via the Medidata Rave Clinical Cloud(TM).

Avance Clinical, Chief Strategy Officer Ben Edwards said "We look forward to many more years working with Medidata as we continue to grow the business and support the development needs of our clients."

Mr Edwin Ng, Senior Vice President, General Manager for Medidata APAC said, "We are pleased to be supporting Avance Clinical's exceptional growth in Australia. Avance Clinical accreditation signifies the importance of Medidata's portfolio of products in ensuring the success of our partners' programs, and our continued commitment to helping our partners streamline and enhance the clinical research process."

Avance Clinical, Director Business Development Operations, Sandrien Louwaars said, "The Medidata Rave Clinical Cloud(TM) is a quality- and efficiency-focused unified platform that helps our biotech clients, and ensures data integrity, speed, and compliance across multisite and global studies.

"Our seven Avance Clinical accredited Medidata experts lead our efforts, and it makes a real difference for our clients having them inhouse rather than as external consultants."

Contact us about your next study. https://www.avancecro.com/eclinical-solutions/

About Avance Clinical - www.avancecro.com

Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.

The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.

Other benefits include:

1. The Government R&D grant means up to 43.5% rebate on clinical trial spend

2. eClinical solutions - speed and continuity

3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks

4. No IND required for clinical trials

5. Full GMP material is not mandated for Phase I clinical trials

6. Established clinical trial environment with world-class Investigators and sites

7. Established healthy subject databases and specialized patient populations

8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care

9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research

10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons

About Medidata - www.medidata.com

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systemes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life Sciences(TM).

Medidata is a registered trademark of Medidata Solutions, Inc., a wholly-owned subsidiary of Dassault Systemes.

About Dassault Systemes - www.3ds.com

Dassault Systemes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systemes brings value to more than 290,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systemes, a French "societe europeenne" (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Media Contact:

Chris Thompson

media@avancecro.com

Koh Shu Mei

shumei.koh@omnicomprgroup

Copyright 2021 ACN Newswire . All rights reserved.

© Japan Corporate News, source JCN Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
DASSAULT SYSTÈMES SE 0.84% 191.25 Real-time Quote.15.11%
All news about DASSAULT SYSTÈMES SE
04/09Atos Teams Up With Dassault, Renault, STM, Thales for Software République Eco..
MT
04/09ATOS, DASSAULT SYSTÈMES, GROUPE RENA : a new open ecosystem for intelligent and ..
PU
04/09ATOS, DASSAULT SYSTÈMES, GROUPE RENA : a new open ecosystem for intelligent and ..
AQ
04/02Airbus and Dassault agree joint FCAS fighter proposal
RE
03/25DASSAULT SYSTEMES  : Medidata Acorn AI Supports EUSA Pharma's Relaunch of SYLVAN..
AQ
03/25DASSAULT SYSTEMES  : Medidata Acorn AI Supports EUSA Pharma's Relaunch of SYLVAN..
AQ
03/24DASSAULT SYSTEMES  : 3DS OUTSCALE Heads to Japan, its Asian Hub
PU
03/23DASSAULT SYSTEMES  : Simulates Airflow in Paris Hospital to Reduce Risks of Expo..
AQ
03/23DASSAULT SYSTEMES  : Joins the European Green Digital Coalition as Founding Memb..
AQ
03/23DASSAULT SYSTÈMES  : Simulates Airflow in Paris Hospital to Reduce Risks of Expo..
BU
More news
Financials
Sales 2021 4 776 M 5 681 M 5 681 M
Net income 2021 700 M 832 M 832 M
Net Debt 2021 1 161 M 1 381 M 1 381 M
P/E ratio 2021 70,4x
Yield 2021 0,43%
Capitalization 49 992 M 59 409 M 59 466 M
EV / Sales 2021 10,7x
EV / Sales 2022 9,62x
Nbr of Employees 19 789
Free-Float 49,8%
Chart DASSAULT SYSTÈMES SE
Duration : Period :
Dassault Systèmes SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DASSAULT SYSTÈMES SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 183,58 €
Last Close Price 191,25 €
Spread / Highest target 12,4%
Spread / Average Target -4,01%
Spread / Lowest Target -22,6%
EPS Revisions
Managers and Directors
NameTitle
Bernard Charlès Vice Chairman & Chief Executive Officer
Dominique Florack President
Pascal Daloz Chief Operating & Financial Officer
Charles Edelstenne Chairman
Laurence Barthès Executive VP, Chief People & Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
DASSAULT SYSTÈMES SE15.11%59 409
MICROSOFT CORPORATION13.86%1 929 676
SEA LIMITED26.06%128 459
ZOOM VIDEO COMMUNICATIONS, INC.-4.35%94 767
ATLASSIAN CORPORATION PLC-3.62%56 364
PALANTIR TECHNOLOGIES INC.2.08%43 807